| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitamin D | 224 | 2022 | 516 | 25.680 |
Why?
|
| Vitamin D Deficiency | 106 | 2020 | 292 | 13.400 |
Why?
|
| Dietary Supplements | 61 | 2022 | 331 | 8.150 |
Why?
|
| Cholecalciferol | 65 | 2020 | 143 | 6.170 |
Why?
|
| Lactation | 24 | 2022 | 110 | 5.170 |
Why?
|
| Pregnancy Complications | 22 | 2022 | 286 | 5.080 |
Why?
|
| Vitamins | 35 | 2022 | 134 | 4.500 |
Why?
|
| Milk, Human | 24 | 2020 | 147 | 4.310 |
Why?
|
| Pregnancy | 72 | 2022 | 2331 | 3.290 |
Why?
|
| Breast Feeding | 19 | 2022 | 159 | 3.280 |
Why?
|
| Parathyroid Hormone | 36 | 2018 | 117 | 2.530 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 10 | 2020 | 37 | 2.440 |
Why?
|
| Calcifediol | 45 | 2017 | 70 | 2.440 |
Why?
|
| Vitamin D-Binding Protein | 21 | 2020 | 58 | 2.320 |
Why?
|
| Calcitriol | 47 | 2013 | 106 | 2.220 |
Why?
|
| Infant Nutritional Physiological Phenomena | 10 | 2020 | 72 | 2.100 |
Why?
|
| Sunlight | 23 | 2020 | 59 | 2.040 |
Why?
|
| Female | 244 | 2022 | 38015 | 2.030 |
Why?
|
| Ergocalciferols | 31 | 2013 | 40 | 1.930 |
Why?
|
| Nutritional Requirements | 14 | 2017 | 57 | 1.870 |
Why?
|
| Humans | 305 | 2022 | 68525 | 1.820 |
Why?
|
| Calcium | 56 | 2022 | 929 | 1.760 |
Why?
|
| Bone Density | 29 | 2022 | 159 | 1.760 |
Why?
|
| Infant, Newborn | 44 | 2020 | 2453 | 1.720 |
Why?
|
| Hydroxycholecalciferols | 25 | 2010 | 29 | 1.560 |
Why?
|
| Adult | 142 | 2021 | 21375 | 1.360 |
Why?
|
| Nutritional Status | 10 | 2019 | 112 | 1.350 |
Why?
|
| Asthma | 12 | 2020 | 345 | 1.260 |
Why?
|
| Infant | 32 | 2022 | 2891 | 1.140 |
Why?
|
| Double-Blind Method | 27 | 2022 | 1737 | 1.040 |
Why?
|
| Milk | 8 | 2011 | 43 | 1.010 |
Why?
|
| Receptors, Calcitriol | 18 | 2012 | 49 | 0.980 |
Why?
|
| Infant, Premature | 7 | 2018 | 284 | 0.970 |
Why?
|
| Pregnancy Trimesters | 2 | 2020 | 14 | 0.960 |
Why?
|
| Male | 151 | 2021 | 37281 | 0.930 |
Why?
|
| Colorectal Neoplasms | 14 | 2020 | 560 | 0.910 |
Why?
|
| Prostatic Neoplasms | 13 | 2016 | 778 | 0.900 |
Why?
|
| Biomarkers | 25 | 2021 | 1593 | 0.890 |
Why?
|
| Prenatal Care | 6 | 2020 | 117 | 0.840 |
Why?
|
| Fetal Blood | 12 | 2020 | 131 | 0.830 |
Why?
|
| Pre-Eclampsia | 7 | 2019 | 202 | 0.810 |
Why?
|
| Skin Pigmentation | 9 | 2008 | 25 | 0.810 |
Why?
|
| Risk Factors | 48 | 2020 | 5719 | 0.790 |
Why?
|
| Bottle Feeding | 1 | 2020 | 20 | 0.760 |
Why?
|
| Prenatal Exposure Delayed Effects | 5 | 2020 | 154 | 0.750 |
Why?
|
| Clinical Laboratory Techniques | 4 | 2008 | 60 | 0.740 |
Why?
|
| Bone and Bones | 23 | 2010 | 145 | 0.730 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2018 | 929 | 0.710 |
Why?
|
| Radioimmunoassay | 17 | 2010 | 164 | 0.710 |
Why?
|
| Skin | 13 | 2020 | 451 | 0.700 |
Why?
|
| Middle Aged | 97 | 2021 | 21119 | 0.680 |
Why?
|
| Young Adult | 32 | 2021 | 5708 | 0.670 |
Why?
|
| Hormones | 2 | 2017 | 42 | 0.660 |
Why?
|
| Nutrition Policy | 6 | 2019 | 44 | 0.660 |
Why?
|
| Immunity, Innate | 4 | 2020 | 156 | 0.650 |
Why?
|
| Gene Deletion | 1 | 2019 | 235 | 0.650 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2017 | 5 | 0.640 |
Why?
|
| Therapeutics | 1 | 2017 | 7 | 0.640 |
Why?
|
| Infant, Very Low Birth Weight | 2 | 2018 | 69 | 0.630 |
Why?
|
| Diet | 21 | 2019 | 513 | 0.630 |
Why?
|
| Prospective Studies | 39 | 2019 | 3702 | 0.620 |
Why?
|
| Dose-Response Relationship, Drug | 21 | 2020 | 1745 | 0.620 |
Why?
|
| Pregnancy Trimester, First | 4 | 2016 | 43 | 0.620 |
Why?
|
| Dihydroxycholecalciferols | 17 | 2008 | 19 | 0.610 |
Why?
|
| Premature Birth | 2 | 2017 | 148 | 0.570 |
Why?
|
| Surveys and Questionnaires | 15 | 2019 | 2798 | 0.570 |
Why?
|
| Calcium, Dietary | 10 | 2021 | 35 | 0.560 |
Why?
|
| Seasons | 12 | 2016 | 129 | 0.560 |
Why?
|
| Endocrine System | 2 | 2013 | 11 | 0.560 |
Why?
|
| Maternal Welfare | 2 | 2012 | 17 | 0.560 |
Why?
|
| Aged | 69 | 2020 | 14842 | 0.550 |
Why?
|
| Adenocarcinoma | 6 | 2019 | 475 | 0.540 |
Why?
|
| Food, Fortified | 6 | 2021 | 38 | 0.530 |
Why?
|
| Obstetric Labor, Premature | 1 | 2015 | 76 | 0.530 |
Why?
|
| Ultraviolet Rays | 14 | 2015 | 130 | 0.530 |
Why?
|
| Birth Weight | 3 | 2020 | 186 | 0.530 |
Why?
|
| Osteocalcin | 15 | 2010 | 37 | 0.510 |
Why?
|
| Autocrine Communication | 2 | 2013 | 37 | 0.490 |
Why?
|
| Body Mass Index | 14 | 2021 | 866 | 0.490 |
Why?
|
| Phascolarctidae | 1 | 2013 | 1 | 0.470 |
Why?
|
| Adolescent | 31 | 2020 | 8903 | 0.470 |
Why?
|
| Animals | 60 | 2017 | 20877 | 0.460 |
Why?
|
| Intestinal Absorption | 7 | 2001 | 41 | 0.460 |
Why?
|
| Leiomyoma | 1 | 2013 | 28 | 0.460 |
Why?
|
| Uterine Neoplasms | 1 | 2013 | 99 | 0.450 |
Why?
|
| Nutrition Assessment | 3 | 2008 | 43 | 0.450 |
Why?
|
| Risk | 11 | 2017 | 563 | 0.430 |
Why?
|
| Pregnancy Outcome | 4 | 2019 | 157 | 0.430 |
Why?
|
| Body Composition | 4 | 2018 | 119 | 0.430 |
Why?
|
| Parathyroid Hormone-Related Protein | 7 | 2011 | 15 | 0.430 |
Why?
|
| Bone Resorption | 14 | 2011 | 64 | 0.420 |
Why?
|
| Bone Remodeling | 5 | 2011 | 45 | 0.410 |
Why?
|
| Cohort Studies | 22 | 2017 | 2356 | 0.410 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2019 | 627 | 0.400 |
Why?
|
| Ursidae | 1 | 2011 | 1 | 0.400 |
Why?
|
| Food, Formulated | 1 | 2011 | 11 | 0.400 |
Why?
|
| Steroid Hydroxylases | 8 | 2012 | 19 | 0.390 |
Why?
|
| Breast Neoplasms | 8 | 2018 | 1533 | 0.390 |
Why?
|
| Postpartum Period | 6 | 2020 | 67 | 0.390 |
Why?
|
| Osteoporosis | 7 | 2005 | 88 | 0.380 |
Why?
|
| Antimicrobial Cationic Peptides | 5 | 2016 | 21 | 0.380 |
Why?
|
| Hypercalcemia | 7 | 2014 | 34 | 0.380 |
Why?
|
| Respiratory Sounds | 4 | 2020 | 35 | 0.380 |
Why?
|
| Uterus | 6 | 2004 | 77 | 0.380 |
Why?
|
| Rickets | 10 | 2017 | 20 | 0.370 |
Why?
|
| Follow-Up Studies | 18 | 2020 | 3256 | 0.360 |
Why?
|
| Child, Preschool | 22 | 2020 | 3185 | 0.360 |
Why?
|
| 25-Hydroxyvitamin D 2 | 12 | 2021 | 16 | 0.360 |
Why?
|
| Absorptiometry, Photon | 9 | 2018 | 83 | 0.360 |
Why?
|
| Treatment Outcome | 16 | 2021 | 7028 | 0.360 |
Why?
|
| Adiponectin | 2 | 2021 | 52 | 0.360 |
Why?
|
| Case-Control Studies | 27 | 2013 | 1548 | 0.350 |
Why?
|
| Logistic Models | 13 | 2017 | 1419 | 0.350 |
Why?
|
| Fetus | 2 | 2022 | 157 | 0.340 |
Why?
|
| Chromatography, High Pressure Liquid | 15 | 2007 | 381 | 0.340 |
Why?
|
| Mothers | 4 | 2022 | 172 | 0.330 |
Why?
|
| Obesity | 7 | 2020 | 1074 | 0.330 |
Why?
|
| Placenta | 3 | 2022 | 101 | 0.330 |
Why?
|
| Child | 26 | 2022 | 6400 | 0.330 |
Why?
|
| Neoplasms | 9 | 2015 | 1660 | 0.330 |
Why?
|
| Intestinal Mucosa | 4 | 2008 | 219 | 0.320 |
Why?
|
| Radioligand Assay | 9 | 2010 | 109 | 0.320 |
Why?
|
| Administration, Oral | 7 | 2019 | 411 | 0.310 |
Why?
|
| Cognition Disorders | 1 | 2011 | 342 | 0.310 |
Why?
|
| Bone Density Conservation Agents | 5 | 2014 | 43 | 0.310 |
Why?
|
| Polymorphism, Genetic | 6 | 2011 | 301 | 0.300 |
Why?
|
| Vitamin B Deficiency | 1 | 2006 | 1 | 0.300 |
Why?
|
| Alkaline Phosphatase | 11 | 2010 | 71 | 0.300 |
Why?
|
| Aging | 10 | 2005 | 911 | 0.290 |
Why?
|
| Gestational Age | 5 | 2020 | 389 | 0.290 |
Why?
|
| Time Factors | 21 | 2020 | 4655 | 0.280 |
Why?
|
| Iodine Radioisotopes | 5 | 2014 | 119 | 0.280 |
Why?
|
| Clinical Trials as Topic | 5 | 2015 | 848 | 0.280 |
Why?
|
| Aged, 80 and over | 23 | 2018 | 4843 | 0.280 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 100 | 0.280 |
Why?
|
| Ovariectomy | 9 | 2000 | 49 | 0.280 |
Why?
|
| Linear Models | 4 | 2018 | 521 | 0.280 |
Why?
|
| Isoflavones | 3 | 2000 | 31 | 0.270 |
Why?
|
| Alzheimer Disease | 1 | 2011 | 563 | 0.270 |
Why?
|
| Athletes | 4 | 2019 | 40 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2021 | 1085 | 0.270 |
Why?
|
| Cross-Sectional Studies | 11 | 2017 | 2264 | 0.270 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2015 | 19 | 0.260 |
Why?
|
| United States | 17 | 2017 | 7335 | 0.260 |
Why?
|
| Adipose Tissue | 2 | 2018 | 221 | 0.260 |
Why?
|
| Yogurt | 2 | 2021 | 2 | 0.260 |
Why?
|
| Reference Values | 9 | 2008 | 579 | 0.250 |
Why?
|
| Age Factors | 12 | 2020 | 1860 | 0.250 |
Why?
|
| Multiple Sclerosis | 3 | 2011 | 132 | 0.240 |
Why?
|
| Body Weight | 8 | 2016 | 554 | 0.240 |
Why?
|
| C-Peptide | 2 | 2015 | 23 | 0.240 |
Why?
|
| Phosphorus | 16 | 2017 | 64 | 0.240 |
Why?
|
| Genotype | 9 | 2012 | 785 | 0.240 |
Why?
|
| Inflammation | 5 | 2019 | 1030 | 0.240 |
Why?
|
| Cytokines | 5 | 2020 | 866 | 0.240 |
Why?
|
| Lumbar Vertebrae | 3 | 2001 | 112 | 0.230 |
Why?
|
| Prostate | 2 | 2016 | 116 | 0.230 |
Why?
|
| South Carolina | 5 | 2015 | 2750 | 0.230 |
Why?
|
| Regression Analysis | 7 | 2020 | 737 | 0.230 |
Why?
|
| Binding, Competitive | 6 | 2010 | 165 | 0.230 |
Why?
|
| Analysis of Variance | 8 | 2009 | 1039 | 0.230 |
Why?
|
| Creatinine | 8 | 2006 | 243 | 0.230 |
Why?
|
| Estradiol | 10 | 2010 | 176 | 0.220 |
Why?
|
| Vascular Resistance | 1 | 2003 | 179 | 0.220 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 4 | 2012 | 21 | 0.220 |
Why?
|
| Rats | 22 | 2012 | 5300 | 0.220 |
Why?
|
| Cytochrome P-450 Enzyme System | 4 | 2003 | 62 | 0.220 |
Why?
|
| Cattle | 14 | 1991 | 475 | 0.220 |
Why?
|
| Cardiovascular Diseases | 4 | 2014 | 938 | 0.220 |
Why?
|
| Osteogenesis | 4 | 2011 | 152 | 0.210 |
Why?
|
| Sensitivity and Specificity | 9 | 2008 | 1753 | 0.210 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2001 | 44 | 0.210 |
Why?
|
| Nutrition Surveys | 2 | 2019 | 204 | 0.210 |
Why?
|
| Premenopause | 5 | 2011 | 57 | 0.210 |
Why?
|
| Helicobacter Infections | 2 | 1999 | 40 | 0.210 |
Why?
|
| Fetal Development | 2 | 2013 | 70 | 0.210 |
Why?
|
| Helicobacter pylori | 2 | 1999 | 54 | 0.210 |
Why?
|
| Sirtuins | 1 | 2021 | 16 | 0.200 |
Why?
|
| Colonic Neoplasms | 4 | 2011 | 299 | 0.200 |
Why?
|
| Basal Metabolism | 1 | 2021 | 22 | 0.200 |
Why?
|
| Incidence | 11 | 2020 | 1582 | 0.200 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2001 | 8 | 0.200 |
Why?
|
| Sirtuin 1 | 1 | 2021 | 47 | 0.200 |
Why?
|
| Thyroid Hormones | 1 | 2021 | 31 | 0.200 |
Why?
|
| Pregnancy Trimester, Third | 4 | 2016 | 39 | 0.200 |
Why?
|
| Calcification, Physiologic | 3 | 1999 | 31 | 0.200 |
Why?
|
| Prognosis | 9 | 2020 | 2093 | 0.200 |
Why?
|
| Prevalence | 13 | 2013 | 1609 | 0.200 |
Why?
|
| Feeding Methods | 1 | 2020 | 17 | 0.190 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2000 | 5 | 0.190 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 37 | 0.190 |
Why?
|
| Cross-Over Studies | 3 | 2019 | 260 | 0.190 |
Why?
|
| Kidney | 11 | 2011 | 945 | 0.190 |
Why?
|
| Airway Resistance | 1 | 2020 | 7 | 0.190 |
Why?
|
| Metronidazole | 2 | 1999 | 28 | 0.190 |
Why?
|
| Lung Neoplasms | 4 | 2012 | 1172 | 0.190 |
Why?
|
| Immunoassay | 1 | 2020 | 64 | 0.180 |
Why?
|
| Estrogens | 4 | 1998 | 173 | 0.180 |
Why?
|
| Sunflower Oil | 1 | 2019 | 1 | 0.180 |
Why?
|
| Dental Enamel Hypoplasia | 1 | 2019 | 5 | 0.180 |
Why?
|
| Cooking | 1 | 2019 | 19 | 0.180 |
Why?
|
| Bone Diseases, Metabolic | 2 | 1999 | 30 | 0.180 |
Why?
|
| Clarithromycin | 1 | 1999 | 11 | 0.180 |
Why?
|
| Puberty | 1 | 2019 | 10 | 0.180 |
Why?
|
| Voice | 1 | 2019 | 16 | 0.180 |
Why?
|
| Therapeutic Equivalency | 1 | 2019 | 21 | 0.180 |
Why?
|
| Dosage Forms | 1 | 2019 | 20 | 0.180 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 146 | 0.170 |
Why?
|
| Dental Caries | 1 | 2019 | 40 | 0.170 |
Why?
|
| Seasonal Affective Disorder | 1 | 1999 | 2 | 0.170 |
Why?
|
| Homozygote | 1 | 2019 | 119 | 0.170 |
Why?
|
| Testosterone | 1 | 2019 | 96 | 0.170 |
Why?
|
| Survivors | 2 | 2013 | 254 | 0.170 |
Why?
|
| Phototherapy | 1 | 1999 | 28 | 0.170 |
Why?
|
| Proportional Hazards Models | 7 | 2019 | 791 | 0.170 |
Why?
|
| Adenoma | 3 | 2007 | 132 | 0.170 |
Why?
|
| Vagina | 1 | 2019 | 87 | 0.170 |
Why?
|
| Anti-Infective Agents | 2 | 2011 | 166 | 0.170 |
Why?
|
| Peptide Fragments | 4 | 2005 | 483 | 0.170 |
Why?
|
| Kinetics | 6 | 2008 | 1047 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2020 | 192 | 0.160 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 163 | 0.160 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 150 | 0.160 |
Why?
|
| Chronic Disease | 8 | 2011 | 1329 | 0.160 |
Why?
|
| Prenatal Diagnosis | 1 | 2018 | 73 | 0.160 |
Why?
|
| Infant Nutrition Disorders | 1 | 2017 | 6 | 0.160 |
Why?
|
| Spine | 2 | 2017 | 46 | 0.160 |
Why?
|
| Gene Expression | 3 | 2017 | 770 | 0.160 |
Why?
|
| Meat Products | 1 | 2017 | 8 | 0.160 |
Why?
|
| Parturition | 1 | 2017 | 15 | 0.160 |
Why?
|
| Odds Ratio | 10 | 2013 | 880 | 0.160 |
Why?
|
| Microbiota | 1 | 2019 | 79 | 0.160 |
Why?
|
| Femur Neck | 1 | 2017 | 3 | 0.160 |
Why?
|
| Pediatric Obesity | 1 | 2019 | 91 | 0.160 |
Why?
|
| Ultraviolet Therapy | 2 | 2008 | 9 | 0.160 |
Why?
|
| Pilot Projects | 4 | 2013 | 1341 | 0.160 |
Why?
|
| Nutritive Value | 1 | 2017 | 22 | 0.160 |
Why?
|
| Microsomes, Liver | 2 | 2003 | 44 | 0.160 |
Why?
|
| Sports | 2 | 2016 | 55 | 0.160 |
Why?
|
| Attitude | 1 | 2018 | 121 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.150 |
Why?
|
| Proteins | 3 | 2003 | 473 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.150 |
Why?
|
| Alleles | 3 | 2009 | 386 | 0.150 |
Why?
|
| Area Under Curve | 5 | 2012 | 238 | 0.150 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2017 | 91 | 0.140 |
Why?
|
| Longitudinal Studies | 10 | 2019 | 1054 | 0.140 |
Why?
|
| Chi-Square Distribution | 2 | 2009 | 546 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 346 | 0.140 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2017 | 56 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2077 | 0.140 |
Why?
|
| Systems Analysis | 1 | 2016 | 33 | 0.140 |
Why?
|
| Minerals | 6 | 2011 | 43 | 0.140 |
Why?
|
| Ovarian Neoplasms | 2 | 2009 | 267 | 0.140 |
Why?
|
| Severity of Illness Index | 7 | 2012 | 1851 | 0.140 |
Why?
|
| Hypersensitivity | 2 | 2014 | 52 | 0.140 |
Why?
|
| Homeostasis | 6 | 2021 | 291 | 0.140 |
Why?
|
| Maternal Health | 1 | 2015 | 8 | 0.140 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 1046 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2011 | 785 | 0.140 |
Why?
|
| Immunologic Techniques | 1 | 1995 | 30 | 0.140 |
Why?
|
| Monocytes | 4 | 2011 | 210 | 0.130 |
Why?
|
| Teriparatide | 3 | 2005 | 7 | 0.130 |
Why?
|
| Family Practice | 1 | 2018 | 312 | 0.130 |
Why?
|
| Rectal Neoplasms | 2 | 2011 | 75 | 0.130 |
Why?
|
| Macrophages | 2 | 2011 | 647 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 2 | 2014 | 138 | 0.130 |
Why?
|
| Toll-Like Receptor 2 | 3 | 2011 | 34 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 1999 | 1026 | 0.130 |
Why?
|
| Nephrolithiasis | 1 | 2014 | 9 | 0.130 |
Why?
|
| Membrane Fluidity | 1 | 1994 | 13 | 0.130 |
Why?
|
| Immune System | 2 | 2012 | 63 | 0.130 |
Why?
|
| Transcriptome | 1 | 2016 | 164 | 0.130 |
Why?
|
| Osteoporosis, Postmenopausal | 2 | 2010 | 20 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2012 | 2688 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2008 | 300 | 0.130 |
Why?
|
| Infant, Low Birth Weight | 2 | 1992 | 84 | 0.120 |
Why?
|
| Protein Binding | 6 | 2008 | 1027 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2011 | 110 | 0.120 |
Why?
|
| Hydrochlorothiazide | 1 | 2014 | 15 | 0.120 |
Why?
|
| Life Style | 2 | 2019 | 338 | 0.120 |
Why?
|
| Hepcidins | 1 | 2013 | 6 | 0.120 |
Why?
|
| Health Promotion | 1 | 2018 | 407 | 0.120 |
Why?
|
| Endocrine System Diseases | 1 | 2013 | 11 | 0.120 |
Why?
|
| Hypertension | 3 | 2013 | 1531 | 0.120 |
Why?
|
| District of Columbia | 1 | 2013 | 23 | 0.120 |
Why?
|
| Blood Pressure | 4 | 2013 | 1447 | 0.120 |
Why?
|
| Soybean Proteins | 4 | 1998 | 11 | 0.110 |
Why?
|
| Amino Acids | 3 | 2011 | 131 | 0.110 |
Why?
|
| Kallikreins | 1 | 2014 | 323 | 0.110 |
Why?
|
| Community Health Centers | 1 | 2012 | 26 | 0.110 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2012 | 756 | 0.110 |
Why?
|
| Recurrence | 4 | 2017 | 948 | 0.110 |
Why?
|
| Crohn Disease | 1 | 2013 | 38 | 0.110 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 15 | 0.110 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2011 | 103 | 0.110 |
Why?
|
| Neoplasm Staging | 5 | 2019 | 799 | 0.110 |
Why?
|
| rho-Associated Kinases | 1 | 2012 | 32 | 0.110 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2012 | 37 | 0.110 |
Why?
|
| Chickens | 6 | 1997 | 232 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2012 | 25 | 0.110 |
Why?
|
| Cathelicidins | 4 | 2016 | 11 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 244 | 0.110 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2012 | 101 | 0.100 |
Why?
|
| Reference Standards | 2 | 2008 | 115 | 0.100 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 57 | 0.100 |
Why?
|
| Risk Assessment | 8 | 2013 | 2004 | 0.100 |
Why?
|
| Systems Biology | 1 | 2011 | 25 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2013 | 203 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 201 | 0.100 |
Why?
|
| Tamoxifen | 1 | 1991 | 62 | 0.100 |
Why?
|
| Fats | 1 | 2011 | 8 | 0.100 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2013 | 307 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 122 | 0.100 |
Why?
|
| Milk Proteins | 1 | 2011 | 22 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 507 | 0.100 |
Why?
|
| Beverages | 2 | 2021 | 50 | 0.100 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2012 | 133 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 240 | 0.100 |
Why?
|
| Vitamin A | 2 | 2008 | 111 | 0.100 |
Why?
|
| Carbohydrates | 1 | 2011 | 57 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2013 | 453 | 0.100 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2011 | 44 | 0.100 |
Why?
|
| Photosynthesis | 1 | 1990 | 3 | 0.100 |
Why?
|
| Critical Illness | 1 | 2012 | 191 | 0.100 |
Why?
|
| Progesterone | 1 | 1991 | 115 | 0.100 |
Why?
|
| Macular Degeneration | 1 | 2011 | 75 | 0.100 |
Why?
|
| Animals, Newborn | 1 | 1991 | 396 | 0.100 |
Why?
|
| Gravidity | 1 | 2010 | 11 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 226 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 529 | 0.100 |
Why?
|
| Hyperparathyroidism | 2 | 1988 | 40 | 0.090 |
Why?
|
| Confidence Intervals | 5 | 2012 | 242 | 0.090 |
Why?
|
| Interferon-gamma | 1 | 2011 | 241 | 0.090 |
Why?
|
| Survival Rate | 3 | 2019 | 1055 | 0.090 |
Why?
|
| Sunscreening Agents | 1 | 1990 | 7 | 0.090 |
Why?
|
| Carcinoma | 1 | 2012 | 215 | 0.090 |
Why?
|
| Collagen | 4 | 1999 | 636 | 0.090 |
Why?
|
| Carrier Proteins | 5 | 1984 | 597 | 0.090 |
Why?
|
| Athletic Injuries | 1 | 2011 | 73 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2012 | 204 | 0.090 |
Why?
|
| Swine | 5 | 2017 | 672 | 0.090 |
Why?
|
| Radius | 2 | 1992 | 10 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 41 | 0.090 |
Why?
|
| Hydroxylation | 2 | 2008 | 41 | 0.090 |
Why?
|
| Diet, Reducing | 2 | 1999 | 46 | 0.090 |
Why?
|
| Psoriasis | 1 | 1990 | 46 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 626 | 0.090 |
Why?
|
| Fatty Acids | 1 | 2011 | 222 | 0.090 |
Why?
|
| Microsomes | 1 | 1989 | 31 | 0.090 |
Why?
|
| Trophoblasts | 1 | 1989 | 29 | 0.090 |
Why?
|
| Procollagen | 3 | 2010 | 31 | 0.090 |
Why?
|
| Georgia | 1 | 2009 | 161 | 0.090 |
Why?
|
| Phosphates | 7 | 2003 | 72 | 0.090 |
Why?
|
| Organ Size | 5 | 2000 | 242 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2011 | 249 | 0.090 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 1293 | 0.090 |
Why?
|
| Athletic Performance | 1 | 2009 | 14 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2000 | 2083 | 0.090 |
Why?
|
| Mitochondria, Liver | 1 | 1990 | 148 | 0.090 |
Why?
|
| United Arab Emirates | 1 | 2009 | 4 | 0.090 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 148 | 0.090 |
Why?
|
| Vitamin D3 24-Hydroxylase | 5 | 2012 | 24 | 0.090 |
Why?
|
| Peptides | 3 | 1998 | 455 | 0.090 |
Why?
|
| Cod Liver Oil | 1 | 2008 | 1 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2009 | 88 | 0.090 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2009 | 36 | 0.090 |
Why?
|
| Bone Development | 4 | 1995 | 37 | 0.090 |
Why?
|
| Humerus | 1 | 1988 | 23 | 0.080 |
Why?
|
| Eating | 4 | 2000 | 119 | 0.080 |
Why?
|
| Food Analysis | 1 | 2008 | 10 | 0.080 |
Why?
|
| Biological Transport | 3 | 2000 | 210 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 378 | 0.080 |
Why?
|
| Statistics, Nonparametric | 3 | 2006 | 306 | 0.080 |
Why?
|
| Mortality | 2 | 2008 | 162 | 0.080 |
Why?
|
| Gastroenteritis | 1 | 2008 | 19 | 0.080 |
Why?
|
| Rats, Inbred Strains | 5 | 1991 | 532 | 0.080 |
Why?
|
| Receptors, Steroid | 3 | 1998 | 13 | 0.080 |
Why?
|
| Ovary | 1 | 1989 | 99 | 0.080 |
Why?
|
| Thymus Gland | 4 | 1991 | 97 | 0.080 |
Why?
|
| Solid Phase Extraction | 1 | 2008 | 4 | 0.080 |
Why?
|
| Dietary Proteins | 1 | 1988 | 51 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2008 | 83 | 0.080 |
Why?
|
| Osteoblasts | 3 | 2005 | 99 | 0.080 |
Why?
|
| Neoplasm Metastasis | 3 | 2019 | 306 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2008 | 91 | 0.080 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 38 | 0.080 |
Why?
|
| Light | 1 | 2008 | 152 | 0.080 |
Why?
|
| Hypocalcemia | 2 | 1991 | 13 | 0.080 |
Why?
|
| Luminescent Measurements | 1 | 2007 | 58 | 0.080 |
Why?
|
| Physicians | 1 | 2011 | 324 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2008 | 248 | 0.070 |
Why?
|
| Colitis | 1 | 2008 | 156 | 0.070 |
Why?
|
| Massachusetts | 2 | 2019 | 28 | 0.070 |
Why?
|
| Indicators and Reagents | 2 | 1997 | 63 | 0.070 |
Why?
|
| Parathyroid Glands | 4 | 1991 | 22 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2009 | 335 | 0.070 |
Why?
|
| Arteries | 2 | 2004 | 108 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 696 | 0.070 |
Why?
|
| Infant Formula | 1 | 2006 | 24 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 56 | 0.070 |
Why?
|
| Chromatography | 4 | 1990 | 47 | 0.070 |
Why?
|
| Hematologic Tests | 2 | 2004 | 24 | 0.070 |
Why?
|
| Cheese | 1 | 2005 | 7 | 0.070 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2004 | 79 | 0.070 |
Why?
|
| Placebos | 2 | 2017 | 195 | 0.070 |
Why?
|
| Biliary Atresia | 3 | 1997 | 7 | 0.070 |
Why?
|
| Spirometry | 2 | 2020 | 47 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 319 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 332 | 0.070 |
Why?
|
| Receptors, Estrogen | 2 | 2011 | 142 | 0.070 |
Why?
|
| Mass Screening | 2 | 2008 | 837 | 0.070 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2000 | 79 | 0.070 |
Why?
|
| Adiposity | 2 | 2016 | 88 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 693 | 0.060 |
Why?
|
| Single-Blind Method | 2 | 2019 | 249 | 0.060 |
Why?
|
| Healthy Volunteers | 2 | 2016 | 78 | 0.060 |
Why?
|
| Bone Diseases | 2 | 1999 | 20 | 0.060 |
Why?
|
| Uremia | 1 | 1984 | 10 | 0.060 |
Why?
|
| No-Observed-Adverse-Effect Level | 1 | 2004 | 5 | 0.060 |
Why?
|
| Mitochondria | 1 | 1989 | 643 | 0.060 |
Why?
|
| Epidermis | 1 | 1984 | 42 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2008 | 2550 | 0.060 |
Why?
|
| Weaning | 2 | 1994 | 12 | 0.060 |
Why?
|
| HIV Infections | 1 | 2012 | 775 | 0.060 |
Why?
|
| Nigeria | 6 | 1999 | 35 | 0.060 |
Why?
|
| Menopause | 4 | 1992 | 47 | 0.060 |
Why?
|
| Netherlands | 2 | 2017 | 68 | 0.060 |
Why?
|
| Blood Glucose | 2 | 2020 | 631 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2003 | 21 | 0.060 |
Why?
|
| Mice | 8 | 2013 | 8472 | 0.060 |
Why?
|
| Regional Blood Flow | 1 | 2003 | 168 | 0.060 |
Why?
|
| 3T3 Cells | 3 | 2013 | 124 | 0.060 |
Why?
|
| Random Allocation | 5 | 2004 | 442 | 0.060 |
Why?
|
| Veterans | 1 | 2011 | 904 | 0.060 |
Why?
|
| Models, Animal | 1 | 2004 | 252 | 0.060 |
Why?
|
| Cholestasis | 2 | 1994 | 90 | 0.060 |
Why?
|
| Microchemistry | 4 | 1986 | 19 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2008 | 807 | 0.050 |
Why?
|
| Cross Reactions | 2 | 1997 | 57 | 0.050 |
Why?
|
| Calcitonin | 3 | 1989 | 21 | 0.050 |
Why?
|
| Transcription Factors | 2 | 1998 | 753 | 0.050 |
Why?
|
| Maryland | 4 | 2012 | 77 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 467 | 0.050 |
Why?
|
| Cleft Palate | 1 | 2002 | 34 | 0.050 |
Why?
|
| Fetal Diseases | 1 | 2002 | 64 | 0.050 |
Why?
|
| Cleft Lip | 1 | 2002 | 33 | 0.050 |
Why?
|
| Diuretics | 2 | 2014 | 96 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2009 | 234 | 0.050 |
Why?
|
| Biological Assay | 3 | 1991 | 88 | 0.050 |
Why?
|
| 24,25-Dihydroxyvitamin D 3 | 5 | 1986 | 6 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2009 | 444 | 0.050 |
Why?
|
| Tibia | 3 | 2000 | 93 | 0.050 |
Why?
|
| Parturient Paresis | 1 | 1981 | 1 | 0.050 |
Why?
|
| Sulfuric Acids | 1 | 1981 | 2 | 0.050 |
Why?
|
| Sulfuric Acid Esters | 1 | 1981 | 7 | 0.050 |
Why?
|
| Leukocyte Count | 2 | 2009 | 94 | 0.050 |
Why?
|
| Intestines | 2 | 2008 | 114 | 0.050 |
Why?
|
| Boston | 2 | 2013 | 35 | 0.050 |
Why?
|
| Plant Extracts | 1 | 2022 | 122 | 0.050 |
Why?
|
| Phytoestrogens | 1 | 2000 | 5 | 0.050 |
Why?
|
| Serum Globulins | 2 | 1977 | 2 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2000 | 98 | 0.050 |
Why?
|
| Plant Preparations | 1 | 2000 | 18 | 0.050 |
Why?
|
| Models, Biological | 3 | 2011 | 981 | 0.050 |
Why?
|
| Heart Failure | 1 | 2009 | 1179 | 0.050 |
Why?
|
| Cell Separation | 1 | 2000 | 132 | 0.050 |
Why?
|
| Postmenopause | 2 | 2005 | 92 | 0.050 |
Why?
|
| CpG Islands | 1 | 2020 | 51 | 0.050 |
Why?
|
| Renal Aminoacidurias | 1 | 1999 | 1 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2001 | 218 | 0.050 |
Why?
|
| Rotavirus Infections | 1 | 1999 | 3 | 0.040 |
Why?
|
| Denmark | 1 | 2019 | 24 | 0.040 |
Why?
|
| Forced Expiratory Volume | 2 | 2010 | 87 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2020 | 114 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 1999 | 70 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2021 | 222 | 0.040 |
Why?
|
| Biological Availability | 2 | 2012 | 79 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2021 | 241 | 0.040 |
Why?
|
| Anthropometry | 3 | 2008 | 64 | 0.040 |
Why?
|
| Diarrhea | 1 | 1999 | 63 | 0.040 |
Why?
|
| Vaginosis, Bacterial | 1 | 2019 | 24 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2013 | 2790 | 0.040 |
Why?
|
| Genetic Markers | 1 | 1999 | 144 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2011 | 114 | 0.040 |
Why?
|
| Hospitalization | 2 | 2009 | 977 | 0.040 |
Why?
|
| Colon | 2 | 2011 | 168 | 0.040 |
Why?
|
| Lipids | 1 | 2020 | 298 | 0.040 |
Why?
|
| Psychological Tests | 1 | 1999 | 96 | 0.040 |
Why?
|
| Research Design | 2 | 2014 | 729 | 0.040 |
Why?
|
| Ulna Fractures | 1 | 1998 | 8 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 180 | 0.040 |
Why?
|
| Calcium Chloride | 1 | 1998 | 38 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2007 | 84 | 0.040 |
Why?
|
| Collagen Type I | 4 | 2005 | 175 | 0.040 |
Why?
|
| Radius Fractures | 1 | 1998 | 17 | 0.040 |
Why?
|
| Osteoarthritis | 1 | 1999 | 73 | 0.040 |
Why?
|
| Tuberculosis | 2 | 2011 | 77 | 0.040 |
Why?
|
| Hip Fractures | 1 | 1998 | 26 | 0.040 |
Why?
|
| Curacao | 1 | 2017 | 1 | 0.040 |
Why?
|
| Peptide Mapping | 1 | 1998 | 39 | 0.040 |
Why?
|
| Malaysia | 1 | 2017 | 6 | 0.040 |
Why?
|
| Vietnam | 1 | 2017 | 36 | 0.040 |
Why?
|
| Tanzania | 1 | 2017 | 35 | 0.040 |
Why?
|
| Pregnancy in Adolescence | 1 | 1997 | 33 | 0.040 |
Why?
|
| Florida | 2 | 2011 | 221 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2019 | 303 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 39 | 0.040 |
Why?
|
| Human Growth Hormone | 1 | 1997 | 20 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 46 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2004 | 58 | 0.040 |
Why?
|
| Cyclic AMP | 2 | 2003 | 223 | 0.040 |
Why?
|
| Child Nutrition Disorders | 1 | 1997 | 5 | 0.040 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1997 | 4 | 0.040 |
Why?
|
| Epidemiologic Studies | 2 | 2011 | 33 | 0.040 |
Why?
|
| Whole-Body Irradiation | 3 | 1992 | 52 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1997 | 150 | 0.040 |
Why?
|
| Osteochondrodysplasias | 1 | 1997 | 3 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 1997 | 138 | 0.040 |
Why?
|
| Wrestling | 1 | 2016 | 2 | 0.040 |
Why?
|
| Gelatin | 1 | 1997 | 14 | 0.040 |
Why?
|
| Goats | 1 | 1997 | 17 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2008 | 1692 | 0.040 |
Why?
|
| Cystic Fibrosis | 1 | 2001 | 283 | 0.040 |
Why?
|
| Dexamethasone | 1 | 1997 | 150 | 0.040 |
Why?
|
| Gastritis | 1 | 1996 | 12 | 0.040 |
Why?
|
| Poultry Diseases | 1 | 1997 | 32 | 0.040 |
Why?
|
| Peptic Ulcer | 1 | 1996 | 37 | 0.040 |
Why?
|
| Periodic Acid | 1 | 1996 | 5 | 0.040 |
Why?
|
| Acetonitriles | 1 | 1996 | 6 | 0.040 |
Why?
|
| Mediterranean Region | 1 | 2016 | 3 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2008 | 1663 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2020 | 718 | 0.040 |
Why?
|
| Rats, Inbred Lew | 2 | 2012 | 150 | 0.030 |
Why?
|
| Homebound Persons | 1 | 1995 | 5 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 502 | 0.030 |
Why?
|
| Nicotinic Acids | 1 | 1995 | 5 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2016 | 87 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2014 | 648 | 0.030 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1995 | 20 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2017 | 116 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1995 | 48 | 0.030 |
Why?
|
| Femur | 2 | 1993 | 113 | 0.030 |
Why?
|
| Consumer Product Safety | 1 | 1995 | 32 | 0.030 |
Why?
|
| Chromatography, Liquid | 2 | 1986 | 120 | 0.030 |
Why?
|
| Frail Elderly | 1 | 1995 | 31 | 0.030 |
Why?
|
| Animal Feed | 1 | 1995 | 52 | 0.030 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1995 | 54 | 0.030 |
Why?
|
| Acid Phosphatase | 2 | 1996 | 36 | 0.030 |
Why?
|
| RNA, Double-Stranded | 1 | 1995 | 13 | 0.030 |
Why?
|
| Dwarfism, Pituitary | 1 | 1995 | 4 | 0.030 |
Why?
|
| Growth Hormone | 1 | 1995 | 51 | 0.030 |
Why?
|
| Microvilli | 1 | 1994 | 22 | 0.030 |
Why?
|
| Fluorescence Polarization | 1 | 1994 | 14 | 0.030 |
Why?
|
| Lung | 1 | 2020 | 849 | 0.030 |
Why?
|
| Body Fluid Compartments | 1 | 2014 | 4 | 0.030 |
Why?
|
| Duodenum | 1 | 1994 | 47 | 0.030 |
Why?
|
| Vitamin E | 2 | 1992 | 55 | 0.030 |
Why?
|
| Finland | 2 | 2009 | 13 | 0.030 |
Why?
|
| Body Size | 1 | 2014 | 39 | 0.030 |
Why?
|
| Injections, Subcutaneous | 3 | 2005 | 87 | 0.030 |
Why?
|
| Diclofenac | 1 | 1994 | 11 | 0.030 |
Why?
|
| Anisotropy | 1 | 1994 | 105 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1995 | 248 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 7 | 0.030 |
Why?
|
| Cation Transport Proteins | 1 | 2013 | 11 | 0.030 |
Why?
|
| Ferritins | 1 | 2013 | 49 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2013 | 68 | 0.030 |
Why?
|
| Blood | 1 | 1993 | 40 | 0.030 |
Why?
|
| Chromatography, Gel | 2 | 1985 | 79 | 0.030 |
Why?
|
| Public Health | 1 | 2015 | 201 | 0.030 |
Why?
|
| Receptors, Angiotensin | 1 | 2013 | 59 | 0.030 |
Why?
|
| Sex Factors | 3 | 2005 | 1265 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2014 | 115 | 0.030 |
Why?
|
| Hydroxyproline | 3 | 1991 | 33 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 1984 | 765 | 0.030 |
Why?
|
| Cholestasis, Intrahepatic | 2 | 1992 | 9 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2013 | 98 | 0.030 |
Why?
|
| Textiles | 1 | 1992 | 3 | 0.030 |
Why?
|
| Clothing | 1 | 1992 | 7 | 0.030 |
Why?
|
| Placenta Growth Factor | 1 | 2012 | 12 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 2012 | 134 | 0.030 |
Why?
|
| Mevalonic Acid | 1 | 2012 | 27 | 0.030 |
Why?
|
| Biosynthetic Pathways | 1 | 2012 | 15 | 0.030 |
Why?
|
| Global Health | 1 | 2013 | 135 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.030 |
Why?
|
| International System of Units | 1 | 2012 | 6 | 0.030 |
Why?
|
| Cell Count | 1 | 1993 | 248 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 2012 | 124 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 1465 | 0.030 |
Why?
|
| SEER Program | 1 | 2013 | 150 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 2012 | 30 | 0.030 |
Why?
|
| Phosphorus, Dietary | 3 | 1997 | 3 | 0.030 |
Why?
|
| Kidney Diseases | 2 | 1986 | 307 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 91 | 0.030 |
Why?
|
| Absorption | 3 | 2005 | 49 | 0.030 |
Why?
|
| Colostrum | 1 | 1991 | 6 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2012 | 122 | 0.030 |
Why?
|
| Tetracycline | 2 | 1996 | 29 | 0.030 |
Why?
|
| Greece | 1 | 2011 | 3 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 76 | 0.030 |
Why?
|
| Lovastatin | 1 | 2012 | 78 | 0.030 |
Why?
|
| Ilium | 1 | 1991 | 16 | 0.030 |
Why?
|
| Fibula | 1 | 1991 | 13 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2009 | 614 | 0.030 |
Why?
|
| Magnesium | 2 | 1986 | 110 | 0.030 |
Why?
|
| Complement Factor H | 1 | 2011 | 21 | 0.030 |
Why?
|
| Ions | 1 | 2011 | 50 | 0.030 |
Why?
|
| Cell Line | 2 | 1995 | 1752 | 0.030 |
Why?
|
| Siblings | 1 | 2011 | 34 | 0.030 |
Why?
|
| Cytosol | 2 | 1984 | 123 | 0.030 |
Why?
|
| ROC Curve | 1 | 2012 | 392 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2011 | 24 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 57 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2012 | 244 | 0.020 |
Why?
|
| Rectum | 1 | 2011 | 62 | 0.020 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2010 | 4 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1994 | 400 | 0.020 |
Why?
|
| Spleen | 1 | 1991 | 301 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 334 | 0.020 |
Why?
|
| Isocitrates | 1 | 1990 | 1 | 0.020 |
Why?
|
| Benzothiadiazines | 1 | 1990 | 4 | 0.020 |
Why?
|
| Ultracentrifugation | 1 | 1990 | 10 | 0.020 |
Why?
|
| Ketoconazole | 1 | 1990 | 6 | 0.020 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2012 | 250 | 0.020 |
Why?
|
| Serum Albumin | 2 | 1989 | 104 | 0.020 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 1990 | 8 | 0.020 |
Why?
|
| Cell Fractionation | 1 | 1990 | 34 | 0.020 |
Why?
|
| Nurses | 1 | 2011 | 53 | 0.020 |
Why?
|
| Weight Gain | 1 | 1991 | 135 | 0.020 |
Why?
|
| Erythema | 1 | 1990 | 18 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 279 | 0.020 |
Why?
|
| NADP | 1 | 1990 | 39 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 1990 | 16 | 0.020 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2010 | 10 | 0.020 |
Why?
|
| Photosensitivity Disorders | 1 | 1990 | 7 | 0.020 |
Why?
|
| Complement System Proteins | 1 | 2011 | 135 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 447 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2011 | 2673 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1990 | 38 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1174 | 0.020 |
Why?
|
| Canada | 1 | 2011 | 266 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 1990 | 56 | 0.020 |
Why?
|
| PAX5 Transcription Factor | 1 | 2010 | 9 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 285 | 0.020 |
Why?
|
| Phosphopeptides | 1 | 2010 | 8 | 0.020 |
Why?
|
| Energy Intake | 1 | 1991 | 123 | 0.020 |
Why?
|
| Musculoskeletal Diseases | 1 | 2010 | 45 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 361 | 0.020 |
Why?
|
| Iowa | 2 | 2006 | 33 | 0.020 |
Why?
|
| Rats, Inbred SHR | 1 | 2009 | 95 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 397 | 0.020 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2009 | 1 | 0.020 |
Why?
|
| beta-Defensins | 1 | 2009 | 8 | 0.020 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2009 | 50 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 1989 | 92 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 2003 | 357 | 0.020 |
Why?
|
| Autophagy | 1 | 2011 | 207 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 331 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2010 | 118 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 710 | 0.020 |
Why?
|
| Parity | 2 | 2004 | 71 | 0.020 |
Why?
|
| Costa Rica | 1 | 2009 | 6 | 0.020 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2009 | 6 | 0.020 |
Why?
|
| Bronchial Provocation Tests | 1 | 2009 | 9 | 0.020 |
Why?
|
| Maine | 1 | 2009 | 3 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2010 | 132 | 0.020 |
Why?
|
| Methacholine Chloride | 1 | 2009 | 20 | 0.020 |
Why?
|
| Lithium | 1 | 1989 | 76 | 0.020 |
Why?
|
| Phenotype | 1 | 2012 | 946 | 0.020 |
Why?
|
| Eosinophils | 1 | 2009 | 60 | 0.020 |
Why?
|
| Ligands | 2 | 1998 | 317 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 186 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1990 | 567 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 2009 | 91 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2009 | 371 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2011 | 276 | 0.020 |
Why?
|
| Oregon | 1 | 1988 | 7 | 0.020 |
Why?
|
| Soybeans | 1 | 1988 | 11 | 0.020 |
Why?
|
| Rhode Island | 1 | 1988 | 9 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1988 | 166 | 0.020 |
Why?
|
| Haplotypes | 1 | 2008 | 174 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 2009 | 213 | 0.020 |
Why?
|
| Riboflavin | 1 | 1988 | 15 | 0.020 |
Why?
|
| Arizona | 1 | 2008 | 9 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 1988 | 104 | 0.020 |
Why?
|
| Ohio | 1 | 1988 | 64 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 450 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 52 | 0.020 |
Why?
|
| Dextran Sulfate | 1 | 2008 | 88 | 0.020 |
Why?
|
| Smoking | 3 | 2005 | 1449 | 0.020 |
Why?
|
| Tissue Distribution | 2 | 2000 | 282 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 742 | 0.020 |
Why?
|
| Delivery, Obstetric | 1 | 1988 | 58 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 756 | 0.020 |
Why?
|
| Species Specificity | 2 | 1979 | 302 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2007 | 1 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 186 | 0.020 |
Why?
|
| Stem Cells | 1 | 2009 | 248 | 0.020 |
Why?
|
| Prealbumin | 2 | 1997 | 25 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 1988 | 131 | 0.020 |
Why?
|
| Heart Defects, Congenital | 1 | 2012 | 596 | 0.020 |
Why?
|
| Hawaii | 1 | 2007 | 24 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2005 | 567 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 1037 | 0.020 |
Why?
|
| Scleroderma, Systemic | 1 | 1991 | 446 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 1849 | 0.020 |
Why?
|
| Rehabilitation Centers | 1 | 2007 | 46 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2009 | 432 | 0.020 |
Why?
|
| Mammography | 1 | 2010 | 310 | 0.020 |
Why?
|
| Labor, Obstetric | 1 | 1986 | 23 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1986 | 46 | 0.020 |
Why?
|
| Digestive System Neoplasms | 1 | 2006 | 13 | 0.020 |
Why?
|
| Transcriptional Activation | 2 | 1999 | 226 | 0.020 |
Why?
|
| Myocardium | 1 | 2012 | 1204 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2007 | 157 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2006 | 22 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 349 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 1986 | 39 | 0.020 |
Why?
|
| Serum Albumin, Bovine | 1 | 1985 | 43 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2006 | 77 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2005 | 47 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 954 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2009 | 955 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1985 | 93 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2007 | 291 | 0.020 |
Why?
|
| Silicon Dioxide | 1 | 1985 | 61 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 2 | 1998 | 172 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 179 | 0.020 |
Why?
|
| Health Status | 1 | 2008 | 429 | 0.020 |
Why?
|
| Hypoparathyroidism | 2 | 1984 | 4 | 0.020 |
Why?
|
| Rabbits | 1 | 1985 | 509 | 0.020 |
Why?
|
| Dogs | 1 | 1985 | 490 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2007 | 269 | 0.020 |
Why?
|
| Dehydrocholesterols | 1 | 1984 | 3 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 1984 | 169 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 320 | 0.020 |
Why?
|
| Blood Proteins | 2 | 1995 | 94 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 1998 | 1082 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2006 | 714 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2006 | 201 | 0.020 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2003 | 8 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2003 | 12 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2003 | 22 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1998 | 1446 | 0.010 |
Why?
|
| Maternal Age | 1 | 2004 | 70 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 2004 | 57 | 0.010 |
Why?
|
| Length of Stay | 1 | 2007 | 780 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2003 | 234 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 375 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2004 | 172 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2006 | 682 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1984 | 174 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1984 | 420 | 0.010 |
Why?
|
| Heart Rate | 1 | 2005 | 568 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 508 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2003 | 107 | 0.010 |
Why?
|
| Kidney Tubules | 1 | 2003 | 80 | 0.010 |
Why?
|
| Caseins | 2 | 1998 | 19 | 0.010 |
Why?
|
| Edible Grain | 1 | 2002 | 8 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 2002 | 28 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2004 | 224 | 0.010 |
Why?
|
| Radiography | 2 | 1999 | 572 | 0.010 |
Why?
|
| Health Surveys | 1 | 2004 | 488 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 282 | 0.010 |
Why?
|
| Reproduction | 1 | 2002 | 48 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1982 | 49 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2003 | 274 | 0.010 |
Why?
|
| Immunodiffusion | 1 | 1981 | 19 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 1982 | 71 | 0.010 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2001 | 6 | 0.010 |
Why?
|
| Nephrotic Syndrome | 1 | 1982 | 61 | 0.010 |
Why?
|
| Lipase | 1 | 2001 | 16 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1981 | 103 | 0.010 |
Why?
|
| Tissue Extracts | 1 | 1980 | 10 | 0.010 |
Why?
|
| Pseudohypoparathyroidism | 1 | 1980 | 3 | 0.010 |
Why?
|
| Protein Deficiency | 1 | 1980 | 3 | 0.010 |
Why?
|
| Urban Population | 1 | 2002 | 254 | 0.010 |
Why?
|
| Breast | 1 | 1982 | 137 | 0.010 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2000 | 26 | 0.010 |
Why?
|
| Tritium | 1 | 1980 | 101 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 659 | 0.010 |
Why?
|
| Hyperplasia | 2 | 1991 | 89 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2000 | 146 | 0.010 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 1999 | 3 | 0.010 |
Why?
|
| Minisatellite Repeats | 1 | 1999 | 16 | 0.010 |
Why?
|
| New Zealand | 1 | 1999 | 28 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1999 | 37 | 0.010 |
Why?
|
| Receptors, Androgen | 1 | 1999 | 33 | 0.010 |
Why?
|
| Biomechanical Phenomena | 1 | 2000 | 368 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1979 | 36 | 0.010 |
Why?
|
| Isoelectric Focusing | 1 | 1979 | 42 | 0.010 |
Why?
|
| Calbindins | 1 | 1999 | 23 | 0.010 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 1999 | 6 | 0.010 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 1999 | 21 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1979 | 76 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1999 | 58 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1979 | 272 | 0.010 |
Why?
|
| Hand | 1 | 1999 | 90 | 0.010 |
Why?
|
| Knee Joint | 1 | 1999 | 115 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 1981 | 365 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 1998 | 1 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 1998 | 13 | 0.010 |
Why?
|
| Metyrapone | 1 | 1997 | 3 | 0.010 |
Why?
|
| Gene Library | 1 | 1998 | 68 | 0.010 |
Why?
|
| India | 1 | 1998 | 41 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1997 | 24 | 0.010 |
Why?
|
| Alpha-Globulins | 1 | 1977 | 18 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1998 | 88 | 0.010 |
Why?
|
| Vaccination | 1 | 1999 | 182 | 0.010 |
Why?
|
| Trout | 1 | 1977 | 7 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2000 | 1032 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1997 | 106 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 251 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 1997 | 46 | 0.010 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1997 | 79 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1977 | 358 | 0.010 |
Why?
|
| Half-Life | 1 | 1977 | 96 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 492 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 1977 | 113 | 0.010 |
Why?
|
| Albumins | 1 | 1997 | 72 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 1998 | 322 | 0.010 |
Why?
|
| Immunoradiometric Assay | 1 | 1996 | 3 | 0.010 |
Why?
|
| Antitrichomonal Agents | 1 | 1996 | 5 | 0.010 |
Why?
|
| Causality | 1 | 1997 | 81 | 0.010 |
Why?
|
| Prolactin | 1 | 1996 | 61 | 0.010 |
Why?
|
| Medical Audit | 1 | 1996 | 44 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1998 | 376 | 0.010 |
Why?
|
| Tartrate-Resistant Acid Phosphatase | 1 | 1996 | 22 | 0.010 |
Why?
|
| Homes for the Aged | 1 | 1995 | 16 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1997 | 291 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1995 | 31 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1997 | 175 | 0.010 |
Why?
|
| Nephrocalcinosis | 1 | 1995 | 3 | 0.010 |
Why?
|
| Retinoid X Receptors | 1 | 1995 | 26 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1995 | 25 | 0.010 |
Why?
|
| Blood Donors | 1 | 1995 | 18 | 0.010 |
Why?
|
| Nursing Homes | 1 | 1995 | 54 | 0.010 |
Why?
|
| Organometallic Compounds | 1 | 1996 | 95 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1995 | 118 | 0.010 |
Why?
|
| Tretinoin | 1 | 1995 | 92 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1995 | 60 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 1995 | 107 | 0.010 |
Why?
|
| Alanine | 1 | 1995 | 38 | 0.010 |
Why?
|
| Longevity | 1 | 1995 | 59 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 230 | 0.010 |
Why?
|
| eIF-2 Kinase | 1 | 1995 | 49 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1996 | 308 | 0.010 |
Why?
|
| Retinoids | 1 | 1995 | 122 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1995 | 532 | 0.010 |
Why?
|
| Transfection | 1 | 1995 | 782 | 0.010 |
Why?
|
| Patient Compliance | 1 | 1996 | 402 | 0.010 |
Why?
|
| Chylomicrons | 1 | 1993 | 6 | 0.010 |
Why?
|
| Liver | 1 | 1999 | 1118 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 1015 | 0.010 |
Why?
|
| Wool | 1 | 1992 | 2 | 0.010 |
Why?
|
| Color | 1 | 1992 | 50 | 0.010 |
Why?
|
| Gossypium | 1 | 1992 | 17 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1998 | 902 | 0.010 |
Why?
|
| Menarche | 1 | 1992 | 18 | 0.010 |
Why?
|
| Polyesters | 1 | 1992 | 55 | 0.010 |
Why?
|
| Alagille Syndrome | 1 | 1992 | 1 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1993 | 161 | 0.010 |
Why?
|
| Micelles | 1 | 1992 | 43 | 0.010 |
Why?
|
| Cholesterol | 1 | 1993 | 331 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1991 | 29 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1991 | 137 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1992 | 149 | 0.010 |
Why?
|
| Mexico | 1 | 1990 | 38 | 0.010 |
Why?
|
| Mutation | 1 | 1995 | 1213 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 1988 | 392 | 0.000 |
Why?
|
| Osteomalacia | 1 | 1986 | 8 | 0.000 |
Why?
|
| Nurseries, Hospital | 1 | 1986 | 2 | 0.000 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1986 | 8 | 0.000 |
Why?
|
| Drug Storage | 1 | 1986 | 16 | 0.000 |
Why?
|
| Drug Stability | 1 | 1986 | 71 | 0.000 |
Why?
|
| Filtration | 1 | 1986 | 61 | 0.000 |
Why?
|
| Solutions | 1 | 1986 | 115 | 0.000 |
Why?
|
| Methods | 1 | 1981 | 156 | 0.000 |
Why?
|